<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00575874</url>
  </required_header>
  <id_info>
    <org_study_id>CS011-A-J205</org_study_id>
    <nct_id>NCT00575874</nct_id>
  </id_info>
  <brief_title>Placebo and Active Comparator Controlled Dose Response Study of Rivoglitazone in Type 2 Diabetes</brief_title>
  <acronym>RAISE</acronym>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Dose and Active Comparator-Controlled Dose-Response Study of Rivoglitazone (CS-011) in Patients With Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daiichi Sankyo Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daiichi Sankyo, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to assess the efficacy response of rivoglitazone HCl compared to
      pioglitazone HCl on the placebo-corrected change from baseline in HbA1c after 12 weeks of
      treatment in patients with type 2 diabetes.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2007</start_date>
  <completion_date type="Actual">January 2009</completion_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in HbA1c from baseline for rivoglitazone HCl compared to that for placebo</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Fasting Plasma Glucose from baseline for rivoglitazone HCl compared to that for placebo. Change in HbA1c from baseline compared to that for pioglitazone HCl</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.5 mg rivoglitazone HCl tablets once daily for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1.0 mg rivoglitazone HCl tablets once daily for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1.5 mg rivoglitazone HCl tablets once daily for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>30 mg pioglitazone HCl capsules once daily for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching rivoglitazone HCL placebo tablets and/or matching pioglitazone HCL placebo capsules</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rivoglitazone HCl</intervention_name>
    <description>0.5 mg rivoglitazone HCl tablets once daily for 12 weeks</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rivoglitazone HCl</intervention_name>
    <description>1.0 mg rivoglitazone HCl tablets once daily for 12 weeks</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rivoglitazone HCl</intervention_name>
    <description>1.5 mg rivoglitazone HCl tablets once daily for 12 weeks</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pioglitazone HCl</intervention_name>
    <description>30 mg capsules once daily for 12 weeks</description>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>matching tablets or capsule once daily for 12 weeks</description>
    <arm_group_label>5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  type 2 diabetes

          -  HbA1c &gt;6.5% and &lt;10.0%

          -  FPG &gt;126 mg/dL (7 mmol/L) and &lt; 270 mg/dL (15 mmol/L)

        Exclusion Criteria:

          -  History of type 1 diabetes

          -  History of ketoacidosis

          -  Current insulin therapy

          -  C-peptide &lt;0.5ng/mL

          -  Imparied hepatic function

          -  NYHA Class II-IV cardiac status or hospitalization for CHF or EF&lt;40%

          -  uncontrolled hypertension
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Hong Kong</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 14, 2007</study_first_submitted>
  <study_first_submitted_qc>December 14, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 18, 2007</study_first_posted>
  <last_update_submitted>February 6, 2009</last_update_submitted>
  <last_update_submitted_qc>February 6, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 9, 2009</last_update_posted>
  <responsible_party>
    <name_title>Dr. Alice Pik Shan Kong</name_title>
    <organization>The Chinese University of Hong Kong</organization>
  </responsible_party>
  <keyword>rivoglitazone HCl</keyword>
  <keyword>pioglitazone HCl</keyword>
  <keyword>thiazolidinedione</keyword>
  <keyword>peroxisome proliferator-activated receptor gamma (PPAR gamma)</keyword>
  <keyword>type 2 diabetes mellitus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pioglitazone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

